Symbol | Exchange | Currency |
|---|
INTU inked a deal to buy Mailchimp. CMCSA fell after its CFO warned on subscriber growth. AVO dropped on earnings. BLU rose on clinical trial results. JAMF dipped on a convertible...
Advanced Oncotherapy PLC (LON:AVO) said 2021 is set to be an important year as it aims to have the first LIGHT system generating a full energy beam, alongside the start of treating...
Advanced Oncotherapy PLC’s (LON:AVO) agreement with Saba Partners, an investment consultant in the Gulf region, potentially opens the door to additional markets, says research...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Sell | Sell | Neutral | Buy | Neutral |
| Technical Indicators | Sell | Sell | Strong Sell | Strong Buy | Neutral |
| Summary | Sell | Sell | Sell | Strong Buy | Neutral |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 3.65 | 3.65 | 3.65 | +0.7000 | +23.73% | 199.90M | London | |||
| 19.00 | 19.00 | 19.00 | +2.80 | +17.28% | 2.52M | London | |||
| 1,441.80 | 1,486.20 | 1,422.40 | +7.60 | +0.53% | 10.51M | London | |||
| 306.50 | 306.60 | 300.60 | +5.10 | +1.69% | 3.74M | London | |||
| 491.70 | 496.50 | 489.90 | -3.80 | -0.77% | 4.70M | London | |||
| 5,026.00 | 5,030.00 | 4,952.00 | +40.0 | +0.80% | 346.11K | London | |||
| 190.00 | 190.00 | 190.00 | 0.00 | 0.00% | 0.00 | London | |||
| 11.50 | 11.50 | 11.50 | +0.25 | +2.22% | 77.10K | London | |||
| 4,657.50 | 4,693.50 | 4,640.50 | -67.5 | -1.43% | 2.33M | London | |||
| 33.00 | 33.00 | 33.00 | 0.000 | 0.00% | 21.65K | London | |||
| 104.45 | 105.55 | 103.80 | -0.55 | -0.52% | 14.74M | London | |||
| 421.70 | 425.80 | 414.90 | -3.40 | -0.80% | 3.11M | London | |||
| 21.18 | 21.34 | 20.79 | -0.18 | -0.84% | 2.58M | London | |||
| 823.50 | 833.00 | 823.50 | -7.50 | -0.90% | 625.38K | London | |||
| 1,382.00 | 1,384.00 | 1,374.00 | +10.00 | +0.73% | 377.24K | London |
Advanced Oncotherapy Plc is focused on providing radiotherapy systems for cancer treatment through the use of a proton therapy technology. The Company is engaged in development and then building of the Linac Image Guided Hadron Technology (LIGHT) proton beam cancer therapy device. The Company's segments include Development of Proton Therapy-UK; Development of Proton Therapy-Switzerland; Development of Proton Therapy-USA, and Healthcare-related properties-UK. Its LIGHT system integrates a series of modular linear accelerators. This feature offers hospitals and centers to customize treatment plans based on a range of energies. The Company's Research and development/ADAM S.A. (R&D/ADAM) facility is located on the campus of European Council for Nuclear Research (CERN), Geneva and Switzerland. The Company’s verification and validation site is located in Daresbury, United Kingdom.